Private equity firms are actively pursuing opportunities in the laboratory services sector. Archimed, Astorg, and HCAP are among the investors showing interest, reflecting the growing demand for these services. This trend highlights the increasing focus of private equity on healthcare-related investments, which are often seen as relatively stable and recession-resistant.

In a separate deal, SK Capital is divesting assets in the pharmaceutical supply chain to Siegfried Holding AG. This move suggests strategic portfolio adjustments. SK Capital's decision to sell assets could be driven by a desire to streamline operations or capitalize on favorable market conditions within the pharmaceutical industry.

The heightened interest in lab services and supply chain assets underscores the evolving dynamics within the healthcare and pharmaceutical industries. Investors are seeking to capitalize on opportunities presented by an aging population and increasing demand for healthcare solutions. We will likely see further consolidation and deal activity in both sectors.